196 related articles for article (PubMed ID: 30087117)
1. Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients.
Arshad U; Taubert M; Kurlbaum M; Frechen S; Herterich S; Megerle F; Hamacher S; Fassnacht M; Fuhr U; Kroiss M
Eur J Endocrinol; 2018 Oct; 179(5):287-297. PubMed ID: 30087117
[TBL] [Abstract][Full Text] [Related]
2. Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma.
Kerkhofs TM; Derijks LJ; Ettaieb H; den Hartigh J; Neef K; Gelderblom H; Guchelaar HJ; Haak HR
Ther Drug Monit; 2015 Feb; 37(1):58-65. PubMed ID: 24887633
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
Kerkhofs TM; Baudin E; Terzolo M; Allolio B; Chadarevian R; Mueller HH; Skogseid B; Leboulleux S; Mantero F; Haak HR; Fassnacht M
J Clin Endocrinol Metab; 2013 Dec; 98(12):4759-67. PubMed ID: 24057287
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing.
Yin A; Ettaieb MHT; Swen JJ; van Deun L; Kerkhofs TMA; van der Straaten RJHM; Corssmit EPM; Gelderblom H; Kerstens MN; Feelders RA; Eekhoff M; Timmers HJLM; D'Avolio A; Cusato J; Guchelaar HJ; Haak HR; Moes DJAR
Clin Pharmacokinet; 2021 Jan; 60(1):89-102. PubMed ID: 32607875
[TBL] [Abstract][Full Text] [Related]
5. High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma.
Pape E; Feliu C; Yéléhé-Okouma M; Colling N; Djerada Z; Gambier N; Weryha G; Scala-Bertola J
Oncologist; 2018 Mar; 23(3):389-390. PubMed ID: 29192018
[No Abstract] [Full Text] [Related]
6. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
[TBL] [Abstract][Full Text] [Related]
7. How close are we to personalized mitotane dosing in the treatment of adrenocortical carcinoma? State of the art and future perspectives.
Steenaard RV; Ettaieb MHT; Kerkhofs TMA; Haak HR
Expert Opin Drug Metab Toxicol; 2021 Jun; 17(6):677-683. PubMed ID: 33886381
[TBL] [Abstract][Full Text] [Related]
8. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
[TBL] [Abstract][Full Text] [Related]
9. Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring.
Kerkhofs TM; Derijks LJ; Ettaieb MH; Eekhoff EM; Neef C; Gelderblom H; den Hartigh J; Guchelaar HJ; Haak HR
Eur J Endocrinol; 2014 Dec; 171(6):677-83. PubMed ID: 25201518
[TBL] [Abstract][Full Text] [Related]
10. A case report of a TDM-guided optimization of mitotane for a safe and effective long-term treatment.
Di Paolo A; Ciofi L; Bacca A; Bernini G
J Chemother; 2019 Apr; 31(2):105-108. PubMed ID: 30831058
[TBL] [Abstract][Full Text] [Related]
11. Practical treatment using mitotane for adrenocortical carcinoma.
Terzolo M; Zaggia B; Allasino B; De Francia S
Curr Opin Endocrinol Diabetes Obes; 2014 Jun; 21(3):159-65. PubMed ID: 24732405
[TBL] [Abstract][Full Text] [Related]
12. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.
Mauclère-Denost S; Leboulleux S; Borget I; Paci A; Young J; Al Ghuzlan A; Deandreis D; Drouard L; Tabarin A; Chanson P; Schlumberger M; Baudin E
Eur J Endocrinol; 2012 Feb; 166(2):261-8. PubMed ID: 22048971
[TBL] [Abstract][Full Text] [Related]
13. [Practical use of o,p'DDD in adrenocortical carcinoma].
Bacchetta J; Droz JP
Bull Cancer; 2005 Mar; 92(3):273-9. PubMed ID: 15820922
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients.
Maiter D; Bex M; Vroonen L; T'Sjoen G; Gil T; Banh C; Chadarevian R
Ann Endocrinol (Paris); 2016 Oct; 77(5):578-585. PubMed ID: 27063476
[TBL] [Abstract][Full Text] [Related]
15. The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.
Haider MS; Ahmad T; Groll J; Scherf-Clavel O; Kroiss M; Luxenhofer R
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):575-593. PubMed ID: 34287806
[TBL] [Abstract][Full Text] [Related]
16. [Mitotane in the treatment of adrenal carcinoma].
Sane T
Duodecim; 2010; 126(17):2040-6. PubMed ID: 21053521
[TBL] [Abstract][Full Text] [Related]
17. A simplified method for therapeutic drug monitoring of mitotane by gas chromatography-electron ionization-mass spectrometry.
Ando M; Hirabatake M; Yasui H; Fukushima S; Sugioka N; Hashida T
Biomed Chromatogr; 2020 Mar; 34(3):e4776. PubMed ID: 31826297
[TBL] [Abstract][Full Text] [Related]
18. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer.
Terzolo M; Pia A; Berruti A; Osella G; Alì A; Carbone V; Testa E; Dogliotti L; Angeli A
J Clin Endocrinol Metab; 2000 Jun; 85(6):2234-8. PubMed ID: 10852456
[TBL] [Abstract][Full Text] [Related]
19. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
Chortis V; Taylor AE; Schneider P; Tomlinson JW; Hughes BA; O'Neil DM; Libé R; Allolio B; Bertagna X; Bertherat J; Beuschlein F; Fassnacht M; Karavitaki N; Mannelli M; Mantero F; Opocher G; Porfiri E; Quinkler M; Sherlock M; Terzolo M; Nightingale P; Shackleton CH; Stewart PM; Hahner S; Arlt W
J Clin Endocrinol Metab; 2013 Jan; 98(1):161-71. PubMed ID: 23162091
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane - a case report.
Baszko-Błaszyk D; Ochmańska K; Waśko R; Sowiński J
Endokrynol Pol; 2011; 62(2):186-8. PubMed ID: 21528483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]